Prevalence and Factors Associated with Leishmania infantum Infection of Dogs from an Urban Area of Brazil as Identified by Molecular Methods

Visceral leishmaniasis (VL) is a disease caused by the parasite Leishmania infantum, and dogs are the most important domestic reservoirs of the agent. During recent decades, VL has expanded to large Brazilian urban centers. In the present work, we have demonstrated by using molecular techniques that the rate of canine infection as detected by serology has been considerably underestimated. Two groups of seronegative dogs (infected and non-infected according to molecular methods) were further evaluated from data obtained through interviews with owners of the animals. The factors associated with Leishmania infection in dogs were a family income of less than two minimum salaries, the knowledge of the owner regarding the vector, the dog spending most of its time in the backyard and the dog never having had a previous serological examination. Awareness regarding the factors associated with canine infection will improve health services and the understanding of the disease's expansion in urban areas

Ultrahigh-sensitivity temperature fiber sensor based on multimode interference

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)The proposed sensing device relies on the self-imaging effect that occurs in a pure silica multimode fiber (coreless MMF) section of a single-mode-multimode-single-mode (SMS)-based fiber structure. The influence of the coreless-MMF diameter on the external refractive index (RI) variation permitted the sensing head with the lowest MMF diameter (i.e., 55 mu m) to exhibit the maximum sensitivity (2800 nm/RIU). This approach also implied an ultrahigh sensitivity of this fiber device to temperature variations in the liquid RI of 1.43: a maximum sensitivity of -1880 pm/degrees C was indeed attained. Therefore, the results produced were over 100-fold those of the typical value of approximately 13 pm/degrees C achieved in air using a similar device. Numerical analysis of an evanescent wave absorption sensor was performed, in order to extend the range of liquids with a detectable RI to above 1.43. The suggested model is an SMS fiber device where a polymer coating, with an RI as low as 1.3, is deposited over the coreless MMF; numerical results are presented pertaining to several polymer thicknesses in terms of external RI variation. (C) 2012 Optical Society of America511632363242Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Financiadora de Estudos e Projetos (FINEP)MICRO-PHYTE [PTDC/EBB-EBI/102728/2008]European Union (EU) [SFRH/BD/47799/2008]Portuguese Stateproject COST [299]Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)CAPES [293/11]CAPES [23038.029912/2008-05]MICRO-PHYTE [PTDC/EBB-EBI/102728/2008]European Union (EU) [SFRH/BD/47799/2008]project COST [299

Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study

Background Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third of cases being genetic. Most of this genetic component is accounted for by mutations in GRN, MAPT, and C9orf72. In this study, we aimed to complement previous phenotypic studies by doing an international study of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72. Methods In this international, retrospective cohort study, we collected data on age at symptom onset, age at death, and disease duration for patients with pathogenic mutations in the GRN and MAPT genes and pathological expansions in the C9orf72 gene through the Frontotemporal Dementia Prevention Initiative and from published papers. We used mixed effects models to explore differences in age at onset, age at death, and disease duration between genetic groups and individual mutations. We also assessed correlations between the age at onset and at death of each individual and the age at onset and at death of their parents and the mean age at onset and at death of their family members. Lastly, we used mixed effects models to investigate the extent to which variability in age at onset and at death could be accounted for by family membership and the specific mutation carried. Findings Data were available from 3403 individuals from 1492 families: 1433 with C9orf72 expansions (755 families), 1179 with GRN mutations (483 families, 130 different mutations), and 791 with MAPT mutations (254 families, 67 different mutations). Mean age at symptom onset and at death was 49·5 years (SD 10·0; onset) and 58·5 years (11·3; death) in the MAPT group, 58·2 years (9·8; onset) and 65·3 years (10·9; death) in the C9orf72 group, and 61·3 years (8·8; onset) and 68·8 years (9·7; death) in the GRN group. Mean disease duration was 6·4 years (SD 4·9) in the C9orf72 group, 7·1 years (3·9) in the GRN group, and 9·3 years (6·4) in the MAPT group. Individual age at onset and at death was significantly correlated with both parental age at onset and at death and with mean family age at onset and at death in all three groups, with a stronger correlation observed in the MAPT group (r=0·45 between individual and parental age at onset, r=0·63 between individual and mean family age at onset, r=0·58 between individual and parental age at death, and r=0·69 between individual and mean family age at death) than in either the C9orf72 group (r=0·32 individual and parental age at onset, r=0·36 individual and mean family age at onset, r=0·38 individual and parental age at death, and r=0·40 individual and mean family age at death) or the GRN group (r=0·22 individual and parental age at onset, r=0·18 individual and mean family age at onset, r=0·22 individual and parental age at death, and r=0·32 individual and mean family age at death). Modelling showed that the variability in age at onset and at death in the MAPT group was explained partly by the specific mutation (48%, 95% CI 35–62, for age at onset; 61%, 47–73, for age at death), and even more by family membership (66%, 56–75, for age at onset; 74%, 65–82, for age at death). In the GRN group, only 2% (0–10) of the variability of age at onset and 9% (3–21) of that of age of death was explained by the specific mutation, whereas 14% (9–22) of the variability of age at onset and 20% (12–30) of that of age at death was explained by family membership. In the C9orf72 group, family membership explained 17% (11–26) of the variability of age at onset and 19% (12–29) of that of age at death. Interpretation Our study showed that age at symptom onset and at death of people with genetic frontotemporal dementia is influenced by genetic group and, particularly for MAPT mutations, by the specific mutation carried and by family membership. Although estimation of age at onset will be an important factor in future pre-symptomatic therapeutic trials for all three genetic groups, our study suggests that data from other members of the family will be particularly helpful only for individuals with MAPT mutations. Further work in identifying both genetic and environmental factors that modify phenotype in all groups will be important to improve such estimates. Funding UK Medical Research Council, National Institute for Health Research, and Alzheimer's Society